FGFR
10 drugsFibroblast Growth Factor Receptor
Predictive biomarker for patient selection in 26 indications
Understanding FGFR
What it means: FGFR alterations include fusions, amplifications, and mutations across FGFR1-4. Common in bladder, breast, and cholangiocarcinoma.
Why it matters: FGFR inhibitors (erdafitinib, pemigatinib, futibatinib) target FGFR-altered cancers with good response rates.
Testing: Tested via NGS to identify fusions, mutations, and amplifications across FGFR1-4 genes.
10
Approved Drugs
26
Indications
10
Companies
FGFR is a precision-medicine biomarker linked to 10 FDA-approved targeted drugs from 10 companies, spanning 26 indications including Cholangiocarcinoma, Myeloid/Lymphoid Neoplasms, Renal Cell Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing FGFR drugs below.
Search FGFR Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting FGFR
| Drug | Company | Therapeutic Area |
|---|---|---|
| BALVERSA | Johnson & Johnson | Oncology |
| GAVRETO | RIGEL PHARMS | Oncology |
| ICLUSIG | Takeda | Oncology |
| LENVIMA | EISAI INC | Oncology |
| OFEV | Boehringer Ingelheim | Respiratory |
| PAZOPANIB HYDROCHLORIDE | EUGIA PHARMA | Oncology |
| PEMAZYRE | INCYTE CORP | Oncology |
| RETEVMO | Eli Lilly | Oncology |
| STIVARGA | Bayer | Oncology |
| VOTRIENT | Novartis | Oncology |
FGFR Indications
Cholangiocarcinoma Myeloid/Lymphoid Neoplasms Renal Cell Carcinoma Soft Tissue Sarcoma Advanced renal cell carcinoma Advanced soft tissue sarcoma Non-Small Cell Lung Cancer Medullary Thyroid Cancer Thyroid Cancer Solid Tumors Metastatic colorectal cancer Locally advanced, unresectable or metastatic gastrointestinal stromal tumor Hepatocellular carcinoma Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Systemic Sclerosis-Associated Interstitial Lung Disease Metastatic RET fusion-positive non-small cell lung cancer Advanced or metastatic RET fusion-positive thyroid cancer Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Chronic Myeloid Leukemia Urothelial Carcinoma Locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer Advanced renal cell carcinoma (first-line, in combination with pembrolizumab) Advanced renal cell carcinoma following one prior anti-angiogenic therapy (in combination with everolimus) Unresectable hepatocellular carcinoma (first-line) Advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H) following prior systemic therapy (in combination with pembrolizumab)